Onderneming TrovaGene Inc Nasdaq
Aandelen
US8972383090
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Therapies for Cancers
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +26,42% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +26,42% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04-03-13 |
James Levine
DFI | Director of Finance/CFO | 53 | 12-07-21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11-01-22 |
Chief Tech/Sci/R&D Officer | - | 31-01-23 | |
Vicki Kelemen
COO | Chief Operating Officer | - | 01-01-15 |
Charles Monahan
LAW | General Counsel | - | 11-01-22 |
Brigitte Lindsay
PRN | Corporate Officer/Principal | - | 01-01-12 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22-04-20 |
Gary Pace
BRD | Director/Board Member | 76 | 22-04-20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04-03-13 |
Lâle White
BRD | Director/Board Member | 68 | 22-04-20 |
Mani Mohindru
BRD | Director/Board Member | 52 | 10-06-21 |
Rodney Markin
CHM | Chairman | 67 | 19-02-14 |
Renee Tannenbaum
BRD | Director/Board Member | 72 | 10-06-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 44 724 591 | 41 348 436 ( 92,45 %) | 0 | 92,33 % |
Aandeel B | 0 | 60 600 | 0 | 0 |
Bedrijfsgegevens
Cardiff Oncology, Inc.
11055 Flintkote Avenue
92121, San Diego
+858 952 7570
http://www.cardiffoncology.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |